FDA warned Jackson Health & Wellness Clinic that website claims for Dr. Miller’s teas and supplements make them unapproved and misbranded drugs.
What happened
FDA reviewed the clinic’s websites in October 2022 and January 2023 and found orders for Dr. Miller’s Holy Tea, Super Holy Tea, Ultimate Tea, Be Free Spring Clean Herbal Detox, and Youthin Fatburners. The sites claimed these products could treat or relieve diseases including acid reflux, IBS, Crohn’s disease, high blood pressure, high cholesterol, parasites, viruses, and bacteria. FDA said the claims and testimonials establish the products are drugs, but they are not FDA-approved and lack adequate directions for use.
What FDA found
The websites claim the teas and supplements cure, treat, or prevent diseases, so FDA treats them as drugs.
section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. § 321(g)(1)(B)]The products are new drugs because they are not generally recognized as safe and effective for these uses and lack FDA approval.
sections 201(p), 301(d), and 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]The products are misbranded because they do not have adequate directions for a layperson to use them safely for the claimed diseases.
section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5Some claimed uses are for diseases that cannot be safely self-diagnosed or self-treated without a licensed practitioner, so adequate directions cannot be written.
section 502(f)(1) [21 U.S.C. 352(f)(1)]Website testimonials describing migraine, Crohn’s disease, IBS, and acid reflux relief also show the products are intended as drugs.
section 201(g)(1)(B) [21 U.S.C. § 321(g)(1)(B)]
What FDA wants
FDA asks the company to notify it in writing within 15 working days of receipt of the letter about specific steps taken to address the violations, including steps to prevent recurrence and related documentation. If corrective actions cannot be completed within 15 working days, the company must state the reason for delay and the time within which it will do so.
Who should pay attention
- clinics and practitioners selling own-brand supplements
- dietary supplement brands making disease-treatment claims
- companies that publish customer testimonials as product evidence
This is a summary. Read the original letter on fda.gov.